

## Servier joins Access Accelerated to fight against non-communicable diseases

**Paris, France – April 4<sup>th</sup> 2019. Servier is now participating in Access Accelerated, a global partnership to advance access to non-communicable diseases (NCDs) prevention, treatment and care in low and lower-middle income countries (LMICs).**

Non-communicable diseases (NCDs), also known as chronic diseases, are responsible for 71 percent of global deaths annually and 15 million people who die from an NCD are between the ages of 30 and 69 years. An alarming 85 percent of these premature deaths occur in LMICs<sup>1</sup>. According to World Health Organization, non-communicable diseases tend to be of long duration and are the result of a combination of genetic, physiological, environmental and behaviors factors.

Health systems in LMICs are often not optimized to address this growing burden and people face multiple barriers to prevention, treatment and care. The key responses to contain this scourge mainly consist by detecting, screening and treat NCDs. In this context, centralization seems to appear to be one of the key elements to ensure a better response, for the final benefit of patients.

Now consisting of 26 pharmaceutical companies, Access Accelerated unites industry action and applies member companies' global reach and local expertise to address the NCD burden. By working with international partners, Access Accelerated co-creates scalable and sustainable access solutions, while supporting inclusive local and country-led engagement and ownership.

Through projects such as the training of a pediatric team to facilitate the establishment of [the Cuomo pediatric cardiac care center in Senegal](#), Servier has already implemented a number of initiatives to improve access to healthcare in areas lacking sufficient medical infrastructures<sup>2</sup>. With its participation in Access Accelerated, Servier intends to further expand its efforts to improve access to healthcare for people around the world. Servier has embraced the Access Accelerated commitment to achieve the United Nations Sustainable Development Goals (SDGs), particularly, target 3.4 to reduce premature deaths from NCDs by one-third by 2030.

*“Servier is dedicated to therapeutic progress to serve patient needs. We have a social responsibility to improve access to health for patients. Servier’s participation to Access Accelerated will support this everyday commitment,”* declared Vincent Minvielle, Head of Corporate Social Responsibility at Servier.

<sup>1</sup> World Health Organization, Noncommunicable Diseases Fact Sheet. 1 June 2018. <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>

<sup>2</sup> Servier has also always been involved in philanthropic initiatives in France and abroad, through CSR actions and Mécénat Servier Endowment Fund. This Fund's goal is to promote and take part in community-interest activities or projects, both directly and indirectly, in France and around the world, for actions that align with the Group's values: dare to innovate, care, grow by sharing and commit to succeed. Mécénat Servier is particularly committed to supporting projects and actions in the following action areas: health, education, living together. Learn more : <https://mecenat.servier.com/>



Access Accelerated Director James Pfitzer said “*Servier brings a wealth of knowledge and expertise in NCD care and we are delighted for the company to join Access Accelerated. Servier’s contribution will further bolster our efforts to combat the global NCD crisis and end premature deaths from preventable, treatable diseases.*”

In addition to the individual programs to improve access to health care run by each of the participating companies, this initiative conducts pilots for improving prevention, treatment and care of NCDs in collaboration with the World Bank Group. Moreover, in collaboration with City Cancer Challenge 2025 (CCAN), Access Accelerated supports the provision of effective, sustainable diagnosis and treatment, for the purpose of improving cancer treatment and care.

#### **About Servier**

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

More information: [www.servier.com](http://www.servier.com)

Follow us on Social Media:   

#### **Press contacts:**

Sonia Marques : [media@servier.com](mailto:media@servier.com) – Tél. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13  
Jean-Clément Vergeau : [media@servier.com](mailto:media@servier.com) – Tél. +33 (0)1 55 72 46 16 / + 33 (0) 6 79 56 75 96  
Karine Bousseau : [media@servier.com](mailto:media@servier.com) – Tél. +33 (0)1 55 72 60 37 / + 33 (0) 6 49 92 16 05